Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

GlobalMarketBulletin Jun. 5 at 12:23 AM

$CAPR $IBRX $IOVA $NTLA $BOBS Some of the market’s most shorted small-cap and mid-cap stocks are showing signs of life, with improving revenue, major clinical updates, defense technology momentum, and possible short squeeze potential. https://globalmarketbulletin.com/top-5-heavily-shorted-small-cap-and-mid-cap-stocks-to-buy-today/

0 · Reply

StockJelli Jun. 4 at 10:47 PM

1 out of 3 today. $ABSI +5.8% hit. $NTLA and $SOXS went flat. $SOXS was a leveraged bear ETF that shouldn’t have fired. Getting blocked tonight alongside $DXYZ and other leveraged products. Bad days get posted too. 70 alerts, 73% hit +3%. Every outcome tracked publicly. http://stockjelli.com

0 · Reply

betrump Jun. 4 at 10:39 PM

$NTLA i said so

0 · Reply

Canucks48 Jun. 4 at 10:15 PM

$NTLA it is going to in that direction I like your assessment

0 · Reply

Thewolf76 Jun. 4 at 7:58 PM

$NTLA

0 · Reply

Canucks48 Jun. 4 at 7:16 PM

$NTLA we may see next $26+ let hope by July Aug very bullish

0 · Reply

GoodTidings Jun. 4 at 6:56 PM

$NTLA Revaluation after conference call... Move to $28 has started... Covering can overshoot this to $40... 🤔🤔🤔

0 · Reply

GoodTidings Jun. 4 at 6:53 PM

$NTLA We are writing history here... First approved Invivo Gene therapy... $2000 Stock... 😎😎😎

0 · Reply

APman Jun. 4 at 6:50 PM

$NTLA Am I the only one thinking the market is frothing?

1 · Reply

GoodTidings Jun. 4 at 6:42 PM

$NTLA Shorts are over exposed and stretched to the limit... Capitulation expected and a covering domino might unfold... 😎😎😎

0 · Reply

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 3 days ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

May 20, 2026, 2:35 PM EDT - 15 days ago

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-13T10:34:18.000Z - 22 days ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:28:35.000Z - 22 days ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

May 12, 2026, 6:40 PM EDT - 23 days ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T16:07:18.000Z - 23 days ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T11:12:55.000Z - 23 days ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-11T17:26:11.000Z - 24 days ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

May 11, 2026, 7:30 AM EDT - 24 days ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 24 days ago

Intellia Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:30 AM EDT - 24 days ago

Intellia Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 4 weeks ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

2026-05-02T00:11:02.000Z - 4 weeks ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

May 1, 2026, 4:01 PM EDT - 4 weeks ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Intellia Therapeutics Proxy statement: Proxy filing

2026-04-30T03:26:02.000Z - 5 weeks ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-29T15:02:56.000Z - 5 weeks ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

Apr 29, 2026, 7:00 AM EDT - 5 weeks ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

2026-04-29T00:13:03.000Z - 5 weeks ago

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

2026-04-28T13:00:00.000Z - 5 weeks ago

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

ARKG ARKK ARKQ RKLB

2026-04-28T11:21:47.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $13 from $7 at Baird

2026-04-28T11:12:55.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $58 from $48 at Canaccord

2026-04-28T10:29:23.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $9 from $8 at Goldman Sachs

2026-04-28T09:45:14.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $30 from $28 at Citizens

2026-04-28T00:10:21.000Z - 5 weeks ago

Cathie Wood’s ARK Investment buys 264K shares of Intellia Therapeutics today

2026-04-27T20:06:44.000Z - 5 weeks ago

Intellia Therapeutics announces $150M common stock offering

Apr 27, 2026, 4:01 PM EDT - 5 weeks ago

Intellia Announces Proposed Public Offering of Common Stock

2026-04-27T18:00:53.000Z - 5 weeks ago

Intellia Therapeutics price target raised to $30 from $27 at Chardan

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Intellia Therapeutics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Intellia Therapeutics Slides: Study result

Apr 27, 2026, 7:06 AM EDT - 5 weeks ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:01 AM EDT - 5 weeks ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 24, 2026, 4:05 PM EDT - 5 weeks ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Mar 9, 2026, 8:40 AM EDT - 3 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 3 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 7:40 AM EST - 3 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 8:00 AM EST - 3 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Intellia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 3 months ago

Intellia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Jan 27, 2026, 8:13 AM EST - 4 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 12:00 PM EST - 5 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 5 months ago

Intellia Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:30 AM EST - 5 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 3:17 PM EST - 7 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 7 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 6, 2025, 9:30 AM EST - 7 months ago

Intellia Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 7 months ago

Intellia Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 5:11 PM EDT - 7 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 8:30 AM EDT - 7 months ago

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 7 months ago

Intellia Therapeutics Press release: Study Update

Oct 27, 2025, 7:38 AM EDT - 7 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Intellia Therapeutics Slides: Company Presentation

Sep 25, 2025, 9:52 AM EDT - 9 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 9 months ago

Why big players are pouring millions in THIS biotech stock

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Intellia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 10 months ago

Intellia Therapeutics Earnings release: Q2 2025

Aug 1, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jun 15, 2025, 10:45 AM EDT - 1 year ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Intellia Therapeutics Slides: Corporate Presentation

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

GlobalMarketBulletin Jun. 5 at 12:23 AM

0 · Reply

StockJelli Jun. 4 at 10:47 PM

0 · Reply

betrump Jun. 4 at 10:39 PM

$NTLA i said so

0 · Reply

Canucks48 Jun. 4 at 10:15 PM

$NTLA it is going to in that direction I like your assessment

0 · Reply

Thewolf76 Jun. 4 at 7:58 PM

$NTLA

0 · Reply

Canucks48 Jun. 4 at 7:16 PM

$NTLA we may see next $26+ let hope by July Aug very bullish

0 · Reply

GoodTidings Jun. 4 at 6:56 PM

$NTLA Revaluation after conference call... Move to $28 has started... Covering can overshoot this to $40... 🤔🤔🤔

0 · Reply

GoodTidings Jun. 4 at 6:53 PM

$NTLA We are writing history here... First approved Invivo Gene therapy... $2000 Stock... 😎😎😎

0 · Reply

APman Jun. 4 at 6:50 PM

$NTLA Am I the only one thinking the market is frothing?

1 · Reply

GoodTidings Jun. 4 at 6:42 PM

$NTLA Shorts are over exposed and stretched to the limit... Capitulation expected and a covering domino might unfold... 😎😎😎

0 · Reply

Unicorn2020 Jun. 4 at 6:35 PM

$NTLA After forming multiple bottoms, this may finally be the genuine breakout. The stock was at $201 in July 2021. I'm only asking for $20 by July 2026. Is that too much to ask?

1 · Reply

ktrader1991 Jun. 4 at 5:07 PM

$NTLA gets us back to the 20s

0 · Reply

Shirzo Jun. 4 at 4:52 PM

$NTLA

0 · Reply

BioStock25 Jun. 4 at 4:15 PM

$NTLA what could Intellia be presenting at EAACI as additional data for Lonvo-Z when there’s already a rolling BLA, a successful phase 3 readout.. 🤔 Durability? How quickly crossover patients (from placebo to actual treatment) became attack-free? Whatever it is, it’s definitely good news, right?

0 · Reply

jewell69 Jun. 4 at 4:03 PM

Does anybody know what is better: $HACK or $CIBR New topic s IN JUST 1 acct We sold $XBI at a profit. Still under water by an eyelash in our other account. I had been so afraid of $NTLA mostly cuz ms. Salveen Richter at $GS had it rated as a sell. Today 6/4 it is up +15.21% today Ditto all my other usual suspects (but quite less )

0 · Reply

DvirRatson Jun. 4 at 3:56 PM

$NTLA

0 · Reply

Canucks48 Jun. 4 at 3:53 PM

$NTLA looking good,

0 · Reply

BIOTECH_GURU Jun. 4 at 3:39 PM

$NTLA coiled for a while. Bavk to 20s.

0 · Reply

Michaelthoaicaonguyen Jun. 4 at 3:31 PM

$NTLA need to pass $16 and we fly yall

0 · Reply

BitcoinMillionaire888 Jun. 4 at 3:31 PM

$SPCE made a big call today. i prefer ,$NTLA $CRSP that are about to change the world, literally selling years of life to space tech for valuation and revenue growth reasons. sold All Virgin galactic to buy half of each today, made loss as bought virgin a 5.7. very happy with decision!

0 · Reply

XQuise Jun. 4 at 3:29 PM

$NTLA 🤑🤝🧠👈🏻

0 · Reply

BioStock25 Jun. 4 at 3:28 PM

$NTLA looks like we’re closing at 16 today.

0 · Reply

Market Cap	1.83B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	9,606,000
Avg Vol	5,963,598
Day's Range	N/A - N/A
Shares Out	139.72M
Stochastic %K	91%
Beta	1.92
Analysts	Sell
Price Target	$25.61